Good post Tezzdog, thanks. When I read it I was a bit surprised as it sounds like Reqmed have the jump on PAR but from what I can ascertain its a slightly different path that they have taken tackling RA as opposed to strictly OA. The formulation also sounds a bit different ie involving human monoclonal antibody?
Here is a website with some more info on what it is, how it is to be taken and possible side effects: https://www.versusarthritis.org/about-arthritis/treatments/drugs/sarilumab/
I also had read that they are also involved in the Mt Sinai 'project', the link that Tezzdog provided also suggests that Reqmed and Paradigm might have various territories once the whole thing becomes approved, it sounds like a partnership of sorts?
Definitely do your own research and please add colour to this discussion if you can.
- Forums
- ASX - By Stock
- PAR
- The Future
The Future, page-90
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33599 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 65498 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20000 | 0.230 |
4 | 130009 | 0.225 |
12 | 183076 | 0.220 |
6 | 98958 | 0.215 |
9 | 260864 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 65498 | 1 |
0.245 | 48923 | 2 |
0.250 | 3443 | 1 |
0.260 | 58362 | 1 |
0.270 | 5000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online